OPH1002
Posted by: Georgia Retina in
Research Title: A Phase 3 Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista® (Anti PDGF-B Pegylated Aptamer) Administered in Combination With Lucentis® Compared to Lucentis® Monotherapy in Subjects With Subfoveal Neovascular Age-related Macular Degeneration. Sponsor: Ophthotech Corporation Principal Investigator: Atul Sharma, M.D. Description: Subjects will be randomized in a 1:1 ratio to…
Read More
Ophthotech OPH2003
Posted by: Georgia Retina in
Research Title: A Phase 2B Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura® (Anti-C5 Aptamer) in Subjects With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Sponsor: Ophthotech Corporation Principal Investigator: Atul Sharma, M.D. Description: The objectives of this study are to evaluate the safety and efficacy of intravitreous administration of Zimura®…
Read More PDEX
Posted by: Georgia Retina in
Research Title: Triple Therapy — PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration Sponsor: Bay Area Retina Associates Principal Investigator: Atul Sharma, M.D. Description: The purpose of this study is to compare triple therapy using Photodynamic therapy, intravitreal Dexamethasone and intravitreal Ranibizumab injections versus monotherapy with intravitreal Ranibizumab alone for the treatment of…
Read More Regeneron R2176-3-AMD-1417 CAPELLA
Posted by: Georgia Retina in
Research Title: A Phase 2, Double-Masked, Randomized, Controlled, Multiple-Dose, Regimen-Ranging Study of the Efficacy and Safety of Intravitreal REGN2176-3 in Patients With Neovascular Age-Related Macular Degeneration. Sponsor: Regeneron Pharmaceuticals Principal Investigator: Michael Jacobson, M.D. Description: The primary objective of the study is to explore the effect of REGN2176-3 on the Early Treatment Diabetic Retinopathy Scale (ETDRS) best-corrected visual acuity…
Read More Regeneron R910-3-AMD-1517 ONYX
Posted by: Georgia Retina in
Research Title: A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Realted Macular Degeneration. Sponsor: Regeneron Pharmaceuticals Principal Investigator: Michael Jacobson, M.D. Description: The primary objective of the study is to compare the efficacy of intravitreal (IVT)-administered REGN910-3 compared to intravitreal aflibercept injection (IAI). Start…
Read More Regeneron R910-3-DME-1518 RUBY
Posted by: Georgia Retina in
Research Title: A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema. Sponsor: Regeneron Pharmaceuticals Principal Investigator: Michael Jacobson, M.D. Description: The primary objective of the study is to compare the efficacy of intravitreal (IVT)-administered REGN910-3 compared to intravitreal aflibercept injection (IAI) in improving…
Read More Regeneron VGFTe-OD-1411 PANORAMA
Posted by: Georgia Retina in
Research Title: Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR) Sponsor: Regeneron Pharmaceuticals Principal Investigator: Michael Jacobson, M.D. Description: The primary objective of the study is to assess the efficacy of intravitreal (IVT) aflibercept compared to sham treatment in the improvement of moderately severe to…
Read More RIDE FVF4168g
Posted by: Georgia Retina in
Research Title: A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary to Diabetes Mellitus (RIDE) Sponsor: Genentech Principal Investigator: Michael Jacobson, M.D. Description: This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study of the efficacy and safety of ranibizumab injection in patients with CSME-CI secondary to diabetes mellitus (Type…
Read More RISE FVF4170g
Posted by: Georgia Retina in
Research Title: A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary to Diabetes Mellitus (RISE) Sponsor: Genentech Principal Investigator: Michael Jacobson, M.D. Description: This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study of the efficacy and safety of ranibizumab injection in patients with CSME-CI secondary to diabetes mellitus (Type…
Read More Roche BP29647 AVENUE
Posted by: Georgia Retina in
Research Title: A Multiple-Center, Multiple-Dose and Regimen, Randomized, Active Comparator Controlled, Double-Masked, Parallel Group, 36 Week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RG7716 Administered Intravitreally in Patients With Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. Sponsor: Hoffmanm-La Roche Principal Investigator: Jay Stallman, M.D., F.A.C.S. Description: This study will evaluate the safety, tolerability, pharmacokinetics, and efficacy…
Read More 
